title: Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study.
abstract: OBJECTIVE
  The development of atrophic chronic gastritis (ACG) is multifactorial, involving environment as well as host responses to Helicobacter pylori infection. The aim of this study was to determine factors involved in ACG in a European dyspeptic population.
  
  
  METHODS
  Data concerning sociodemographics, social behaviour, biological aspects, diet, and virulence factors of H pylori strains were collected in a cross sectional study from 19 European centres in 14 countries. Dyspeptic H pylori positive patients with ACG or non-ACG (NACG) at histology were included. Anti-CagA antibodies were evaluated by two immunoblot tests and anti-VacA antibodies by one. Logistic regression models were constructed, and estimated odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated from the coefficients.
  
  
  RESULTS
  Of the 451 patients included in the study, 267 were analysed: 202 had NACG and 65 ACG. Mean age was 44.4 years and 63% were women. Risk factors for atrophy identified by multivariate analysis were: age over 60 years (OR 4.14, 95% CI 1.79-9.58), coffee consumption (OR 2.35, 95% CI 1.07-5.16), sedative consumption (OR 2.17, 95% CI 1.04-4.52), and harbouring anti-CagA and anti-VacA antibodies simultaneously (OR 3.09, 95% CI 1.26-7.56), while the odds were significantly reduced for those with an anxiety score of 6 or more (OR 0.45, 95% CI 0.21-0.99).
  
  
  CONCLUSIONS
  The simultaneous presence of anti-CagA and anti-VacA antibodies enhanced the risk of ACG in European dyspeptic patients. Failure to discern diet and family history as risk factors for ACG may suggest that diet is homogeneous in Europe and that most of the risk factors for ACG identified so far are identical to risk factors for H. pylori infection.
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D004032:Diet / Q000009:adverse effects; D005060:Europe / Q000453:epidemiology; D005260:Female; D005757:Gastritis, Atrophic / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D015438:Health Behavior; D016481:Helicobacter Infections / Q000150:complications* / Q000453:epidemiology / Q000276:immunology; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010375:Pedigree; D012307:Risk Factors
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori